Overview of approved COVID-19 vaccines in the EU, recommendations for use in Sweden and vaccine uptake over time
Authors:
- Björn ZetheliusBZBjörn Zethelius
- Johanna RubinJRJohanna Rubin
- Nicklas PihlströmNPNicklas Pihlström
- Ulla Wändel LimingaULUlla Wändel Liminga
- Helena BackHBHelena Back
- Bernice AronssonBABernice Aronsson
- Anders TegnellATAnders Tegnell
- Ulrika MarkingUMUlrika Marking
- Jonas F. LudvigssonJLJonas F. Ludvigsson
- Sören AnderssonSASören Andersson
- Rickard LjungRLRickard Ljung
Open Access
- 16 October 2025
- journal article
- Published by Uppsala Medical Society in Upsala Journal of Medical Sciences
- Vol. 130, e12937
Abstract
Objective: The aim of this review is to describe the regulatory background of the COVID-19 vaccines, the national recommendations for use issued and vaccine uptake in Sweden. It includes an overview of licensing and relevant safety aspects identified by the European Medicines Agency (EMA) and the national vaccination plan issued by the Public Health Agency (PHA) of Sweden. Materials and methods: Information on dates of licensing and safety aspects of importance identified by EMA published on its website, was compiled and presented in a chronological order. National recommendations on COVID-19-vaccination and vaccinations-data on uptake and coverage using the national-vaccine-register are presented. Results: COVID-19 vaccines development, assessments using rolling review and licensing of the covid-19 vaccines was done in 2020 during less than a year. Large-scale production was implemented. Monthly safety reviews performed by the EMA identified risk for thrombosis with thrombocytopenia syndrome with adenoviral vaccines and myocarditis for mRNA vaccines which led to restrictions in national recommendations for specified groups. National vaccinations were launched in a phased manner during 2021. Persons of high age, risk groups and nursing home personnel were prioritised during primary vaccinations and for initial boosters. In the Swedish population, 85% recieved at least on vaccine dose from the age of 12. At least two doses were recieved by 81% from age 18 and 95% from age 80. Conclusion: Recommendations for national use adhered to relevant adverse drug reactions identified. The vaccine coverage was high. Timelines presented should be considered in follow-up studies of COVID-19-vaccines to manage possible selection bias and confounding.Keywords
This publication has 16 references indexed in Scilit:
- Changing characteristics over time of individuals receiving COVID-19 vaccines in Denmark: A population-based descriptive study of vaccine uptakeScandinavian Journal of Public Health, 2022
- Booster Doses of Anti COVID-19 Vaccines: An Overview of Implementation Policies among OECD and EU CountriesInternational Journal of Environmental Research and Public Health, 2022
- SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million ResidentsJAMA Cardiology, 2022
- Clinical development and approval of COVID-19 vaccinesExpert Review of Vaccines, 2022
- The profile of the COvid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE)Upsala Journal of Medical Sciences, 2021
- Phased Implementation of COVID-19 Vaccination: Rapid Assessment of Policy Adoption, Reach and Effectiveness to Protect the Most Vulnerable in the USInternational Journal of Environmental Research and Public Health, 2021
- Association of Maternal SARS-CoV-2 Infection in Pregnancy With Neonatal OutcomesJAMA, 2021
- Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) & Pharmacovigilance Risk Assessment Committee (PRAC)Basic & Clinical Pharmacology & Toxicology, 2021
- Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysisBMJ, 2020
- Ethical aspects of registry-based research in the Nordic countriesClinical Epidemiology, 2015